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1. INTRODUCTION
                          
Breast cancer is a major and important  malignant disease in the 
Western World. In North America it was the most common malignancy 
among women, accounting for 27 per cent of all female cancers. One in 
14 women can expect to develop breast cancer.
            Breast cancer is one of the more slowly growing tumours which 
therefore renders it suitable for screening programmes. The evolution of 
breast cancer, especially in its preclinical phases, can be measured in 
years or  even decades,  although there are exceptions to this rule in 
which the disease takes on a more aggressive form.
              The disease  progresses from normality to hyperplasia, atypia,  
carcinoma in situ, and finally to invasive cancer. This progression is by 
no means inevitable and, in theory, stages may be missed out. It is also 
possible that a given stage may be permanent or may even regress to a 
more normal state.  Serial  mammography has indirectly indicated that 
the doubling time for human breast cancer is usually of the order 
of 100 to 300 days, although exceptions to this are frequently seen.
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2. AIMS AND OBJECTIVES
               This study was conducted on patients who were treated at the  
Government  Royapettah  Hospital  ,Royapettah  ,  Chennai  14  and 
Government Kilpauk  Medical  college Hospital  ,  Kilpauk, Chennai  10 
during the period 2004 – 2006 . This is a prospective study the aims of 
which are :
1. To  find  the  Age  incidence  of  Locally  Advanced  Breast 
Cancer(LABC).
2. To study the various presentations of LABC.
3. To study the management protocol  used ,  its  rational  and 
relevance to our system of medical care.
4. To study the awareness of the present management protocol 
of surgeons through the cases referred to the institution.
5. To analyze the Disease free survival of patients with LABC.
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REVIEW OF LITERATURE
CROSS SECTION OF THE BREAST
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3.REVIEW OF LITERATURE
3.1 ANATOMY OF THE BREAST
               The breast is a modified sweat gland and extends vertically 
from 2nd to 6th rib and horizontally from lateral part of sternum to anterior 
axillary line. Surgical extent is from the clavicle to the 7 th rib and from 
midline  to  lateral  edge  of  latissmus  dorsi.  The  axillary  tail  of  the 
breast(Spence) is of importance and its sometimes normally palpable, 
in lactation and also pre menstrually.
                The lobule is the basic structural unit of the gland and their 
number and size varies considerably . Over 10 to 100 lobule drain into 
the nipple through 15- 20 lactiferous ducts. Each duct is lined by myo –
epithelial  cells and has a terminal ampulla which can contain milk or 
abnormal secretions.
               The ligaments of cooper are fibrous strands which run from 
the skin into the gland substance and account for the skin changes in 
malignancy.  The  areolar  epithelium  has  both  sweat  glands  and 
sebaceous glands.
                The nipple is covered by thick skin and at its apex contains 
the openings of the lactiferous ducts. It has smooth muscle fibres and is 
an erectile structure.
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 LYMPHATICS OF THE BREAST
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3.2  RISK FACTORS             
                 The cause of breast cancer is unknown. Risk factors for 
breast  cancer  fall  into  three  main  groups:  genetic,  endocrine,  and 
environmental;  each  may  be  of  major,  intermediate,  or  minor 
importance  
3.2.1 Major risk factors
I, Sex:
          Breast cancer is 100 times more common in women than in 
men. In strict epidemiological terms, therefore, female sex is a major 
risk factor for breast cancer, although it is often forgotten as such.
II, Age:
         As for other epithelial cancers the incidence of breast cancer 
increases with age. Breast carcinoma shows rapid rise in age-specific 
rates. Breast cancer rate continues to rise until old  age
III, Previous breast cancer:
         The development of a second breast cancer may be a clinical 
manifestation of multifocal origin of the first cancer or may be an entirely 
new cancer. There appears tobe an overall increased risk of 0.75 per 
cent to 1 per cent per year. This risk appears greatest in young women 
if their initial breast cancer is diagnosed before the age of 40.
IV, Family history:
            A family history breast cancer is associated with an increased 
risk of the disease.The risk is greatest in patients with first-degree 
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relatives (mother or sister) affected,especially if they were under the 
age of 50 when the disease developed. The relative risk of developing 
breast cancer is 
1.7 to 2.5 – breast cancer in a first-degree relative
1.5 among those with an affected second-degree relative. 
V, Parity:
          Nulliparity removes a protective effect against breast cancer. 
Single and nulliparous married women have a relative risk rate of 1.4 
compared to parous women;. 
          Women whose first birth occurred after the age of 30 there 
appeared to be virtually no protective effect, with a relative risk of 0.94. 
           If  the age at  first  birth  is  taken into account,  subsequent 
pregnancies  appear  to  have  no  influence  on  the  risk  of  developing 
breast  cancer.  The  protective  effect  occurs  only  if  the  pregnancy 
continues to full term.
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3.2.2  Intermediate risk factors
I, Age of menarche and menopause:
          Women  whose menarche occurs before the age of 12, have a 
relative risk of 2.30 compared to those starting menstruation after this 
age. This decreases as the age of onset of menstruation increases. The 
risk  of  developing  breast  cancer  also  relates  to  the  age  of  the 
menopause. Artificial  menopause by oophorectomy or irradiation also 
reduces the risk of breast cancer.
II, Irradiation:
          An increased risk of breast cancer has been demonstrated in 
survivors  of  atomic  explosions,  women  treated  by  radiation  for 
postpartum mastitis, and patients receiving multiple chest radiographs 
during  assessment  of  tuberculosis.  This  increased  risk  becomes 
apparent  after  a  latent  period  of  10  to  15  years:  the  effect  is  most 
obvious in women exposed to irradiation when under the age of  35; 
there is little increased risk  in women exposed after the age of 40.
III, Body weight:
            There is a strong relationship between body weight and breast  
cancer although this is critically dependent on age. In women under age 
50 there is  little  correlation.  However,  in the 60 to 69 age group an 
increase  in  weight  from less  than  60  to  70  kg  or  greater  increases 
breast cancer risk to 1.8.
13
IV, Benign breast disease:
           Severe atypia with hyperplasia is associated with a moderately 
increased risk of developing breast cancer.
3.2.3 Minor and controversial risk factors
I, Alcohol:
            Evidence for an association between consumption of alcohol  
and increased liability to breast cancer is becoming stronger, although 
the risk is small (1.5).
II, Diet:
           Although  weight  correlates  with  breast  cancer  risk  the 
relationship  between dietary factors such as fat  or  cholesterol  intake 
have not been shown to be an important factor in the development of 
breast carcinoma.
III, Contraceptive pill:
            The risk with the present day pill with low dose estrogen is 
small.  Those  most  at  risk  are  women  taking  oestrogen-based  oral 
contraceptives early in life and taking them for at least 8 to 10 years.
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IV, Hormone  replacement therapy:
              Small doses of exogenous oestrogen therapy for short periods 
of time in premenopausal women appear to be safe. However, when 
hormone replacements are taken for 8 years or longer there may be an 
increased risk of 1.5 to 2.0.
V, Benign breast disease:
              Some pathological entities, such as multiple papillomatosis and 
hyperplasia  with  gross  atypia,  are  certainly  associated  with  an 
increased  risk  of  breast  cancer  (3.0).Patients  with  recurrent 
macroscopic apocrine cysts may also have a slightly increased risk of 
breast cancer.There is no increased cancer risk for fibroadenoma and 
fibrocystic change.
3.3 PATHOLOGICAL FEATURES OF BREAST CANCER
              The histological assessment of breast cancer is of paramount 
importance in establishing the diagnosis  of  the tumour.  It  also helps 
determine the patient’s prognosis and allows a greater understanding of 
the biology of the disease in any one case. There are many methods of 
pathologically classifying breast cancer whether it  is derived from the 
duct system or the lobule . 
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3.3.1 DUCTAL CARCINOMA OF THE BREAST:
                This is the most common form of breast cancer accounting for 
85 to 90 per cent of all cases. It can conveniently be subdivided into in 
situ and invasive types.
I ,Ductal carcinoma in situ:
                It is a preinvasive form of breast cancer. It is characterized by 
a proliferation of  malignant  breast epithelial  cells, is  confined to the 
duct  system,  and  does  not  invade  the  basement  membrane or 
surrounding tissues.
                  The most important aspect of ductal carcinoma is its  
malignant  potential.  Studies  demonstrate  a  30  to  50  per  cent  of 
ipsilateral  invasive  cancer,  usually  in  the  same  quadrant,  after  an 
interval of some 10 to 15 years. The risk of developing invasive cancer 
depends on the extent of ductal carcinoma in situ.         
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HISTO- PATHOLOGY OF  BREAST CANCER
        
          DUCTAL CA IN SITU                               LOBULAR CA IN SITU
  
  
                                 
           
            
                  CRIBRIFORM CA                                    COMEDO CA
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    MICRO PAPILLARY CA                               MUCINOUS  CA
             
                       TUBULAR  CA               PAGETS DISEASE OF NIPPLE
    
                                             
                                                   INFILTRATING DUCTAL CA
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 There are five main histological types of intraductal carcinoma:
1. Solid type:  Duct lobular unit filled with malignant cells
2. Comedo type : The lesions  undergo central necrosis
3. Cribriform type : They  have a sieve-like appearance.
4. Papillary/micro-papillary :They show papillary projections 
5. Clinging type: They may cling to the duct wall
Comedo and papillary forms are the most common and are both 
associated with multicentric disease; 
Comedo  carcinoma  has  the  greatest  expression  of  both  DNA 
aneuploidy and of the C- erb2 oncogene.
II, Invasive / Infiltrating ductal cancer :
            Invasion of  the basement membrane of the duct is the most 
important criterion for all malignant tumours – the ability to infiltrate into 
surrounding tissue.       
             The majority of invasive ductal cancers fall into the group with 
no  characteristic  microscopic  appearance  .  These  are  described  as 
infiltrating ductal carcinoma, not otherwise specified (NOS).
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III, Infiltrating ductal carcinoma (NOS):
              This is essentially a diagnosis of exclusion, but it accounts for 
about 65 per cent of all invasive mammary cancers. The lack of specific 
and consistent histological features .
IV, Special types of infiltrating ductal carcinoma
 A, Medullary carcinoma
 B, Tubular carcinoma
 C, Mucinous (mucoid) carcinoma
 D, Papillary carcinoma
 E, Cribriform carcinoma
V, Other types of Infiltrating  ductal carcinoma:
 A, Signet ring tumours                  
 B, Clear cell tumours             
 C, Secretory carcinomas
  Inflammatory carcinoma:
-- occurs in all age groups but more common in middle age
-- tumour emboli in dermal lymphatics, giving rise to the red    
    infiltrative  appearance of this condition. 
-- must be differentiated from peau d’orange 
-- Its prognosis is very poor.
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3.3.2 LOBULAR CARCINOMA OF THE BREAST:
               Lobular carcinoma can also be conveniently subdivided into 
in-situ  and  invasive  forms,  depending  on  whether  the  basement 
membrane of the lobule has been invaded by tumour.
I, Lobular carcinoma in situ
             Lobular carcinoma in situ,  is also a preinvasive form of breast 
cancer. The microscopic criteria  are:  uniform proliferation of cells , 
no interstitial spaces and expansion of at least half of the acini in the 
lobular unit
               It  has a high potential  for becoming invasive. Lobular 
carcinoma in situ rarely expresses the C- erb2 oncogene.
             The risk of invasive cancer after diagnosis of lobular carcinoma 
in situ (relative risk, 10) relates equally to both breasts. It is a risk factor 
for tumour development rather than a direct precursor. Atypical lobular 
hyperplasia has a 4-fold increased risk  of  cancer.
II, Invasive lobular cancer
             It  accounts for about 10 per cent of  all  cases of  breast 
carcinoma, although its incidence varies quite widely. 
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   Five main subtypes of Invasive lobular cancer  are described: 
                                   A, classical
                                    B,  solid 
                                    C, alveolar
                                    D, mixed
                                    E, pleomorphic. 
          Histologically there is  Indian filing  in a targetoid pattern  in the 
classical  variety.  In  others  there  is  a  lack  of  a  specific  histologic 
architecture . 
               Frequently produces distortion of the breast rather than a 
lump. The prognosis of classic type better than that of invasive ductal 
cancer and other types of lobular carcinoma       
 III ,Labelling index 
           It is the percentage of cells undergoing cell division at any 
particular time. 
High  labelling  indices   short  doubling  times  more  aggressive. 
Median labelling index is about 3 per cent; 
High labelling indices  poor prognosis and outcome
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3.4 THE SPREAD OF BREAST CANCER           
3.4.1 LOCAL SPREAD WITHIN THE BREAST:
           Within the breast there are three main mechanisms of spread. 
I, Direct infiltration (The most important )
                  This occurs by the ramifying projections that give the 
characteristic  macroscopic  stellate  appearance  of  breast  cancer.  If 
uncontrolled, direct infiltration of overlying skin or the underlying fascia 
occurs.
II ,Direct infiltration along ducts           
           Multifocality is due to wide spread in situ cancer. The incidence 
and extent of multifocality depends on the size of the primary tumour..
Multifocality is presence of  cancer within the same quadrant as 
the primary tumour. 
Multicentricity is the presence of carcinoma outside the quadrant 
containing the primary tumour. 
III, Local lymphatic and vascular spread 
    Lymphatic  pathways  extending  into  the pectoral  fascia  and sub-
areolar regions.
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3.4.2 REGIONAL SPREAD OF BREAST CANCER
               The regional spread of breast cancer is defined as that to the 
axillary, internal mammary, and supraclavicular nodes.
 I, Axillary Nodal Spread
             The axillary nodes represent the most important site of regional 
spread from breast cancer. 
Spread to axillary nodes is  the most  important  prognostic 
indicator of breast cancer: approximately 45 per cent of all patients have 
nodal disease at presentation.
             The likelihood of axillary nodal spread is a function of the 
size of the primary tumour
SIZE OF PRIMARY
In cm
INCIDENCE OF 
AXILLARY
NODES
< 2cm < 20 %
2 to 5cm 35%
>5 cm 50%
                              
             About 30 per cent of palpable and apparently diseased 
nodes are found to be histologically free of metastases and vice 
versa
               Techniques such as clearing the axillary fat with xylene to 
increase  nodal  yield  and  more  thorough  sectioning  of  the  nodes 
themselves increase the positivity rate.  
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         The relationship between axillary nodal spread and prognosis 
depends on three factors:
A,Number of nodes involved         
    According  to  studies  National  Surgical  Adjuvant  Breast  Project 
(NSABP)  the number of positive nodes correlates directly with survival 
with 4 or  more nodes being associated with worse prognosis.
        The number of negative nodes  have no prognostic importance. To 
ensure that the axilla is clear of metastases at least four, and possibly 
up to 10, negative nodes must be isolated.
 
B, Level of nodal disease
             The axillary nodes are conveniently divided into three groups 
depending  on  their  relationship  to  the  pectoralis  minor  muscle. 
Prognosis relates to the level of axillary node affected, although this is a 
less  powerful  factor  than the  total  number  of  nodes  affected  by the 
tumour.
Level of nodes 5 yr survival rate
I 65 %
II 31 %
III < 3 %
  C, The extent of disease in individual axillary nodes
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                In  practice  the prognosis  for  patients  with  a  single 
micrometastasis can be regarded as similar to those with node-negative 
disease. Extra nodal disease is associated with bad prognosis.
 II, Internal Mammary Nodal Spread
             Internal mammary nodes are more commonly associated with 
medial or periareolar tumours.  They are involved in 20 per cent of 
cases. Internal mammary  nodal disease  alone is rare and is only 8 %
             It has the same prognostic implication as axillary nodal disease. 
However, if both the internal mammary and axillary nodes are affected 
10-year survival rate is only 25%.    
III, Supraclavicular Nodes
            Involvement  of  Supraclavicular  nodes  implies  extensive 
involvement of the internal mammary or axillary nodes. Supraclavicular 
nodal disease is associated with a poor prognosis.
3.5, THE CLINICAL PRESENTATION OF BREAST CANCER
             The majority of women presenting with breast cancer complain 
of  a  lump.  Classically  this  is  hard,  painless,  immobile,  fixity  to 
surrounding tissues, skin, underlying pectoral muscle. 
Not all breast cancers are hard: they are often  firm. 
The degree of mobility can also vary . It is therefore, advisable to 
undertake histological and cytological examination of any discrete lump 
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in a woman over the age of 25. A diagnosis of a fibroadenoma or cystic 
change without such confirmation is extremely dangerous.
A, Lump:
               A lump is  the presenting feature in 85 % of cases . This is 
not  the case in lobular  carcinoma.  The diffuse nature  of  the  tumour 
produces distortion, puckering, and the eventual feeling of heaviness 
. Later there may be nipple retraction and discomfort. 
B, Pain :
            Pain is not a common feature in carcinoma of the breast. It 
usually indicates an inflammatory process. 
Not  all  cancers  are painless  and have occasionally  increased 
discomfort in the lump prior to menstruation. 
         
    NIPPLE RETRACTION WITH PEAU D’ ORANGE
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CLASSICAL PEAU D’ ORANGE
           
28
C, Changes in the skin:
           It may present with  dimpling tethering or Puckering.             
            Peau d’orange is a feature of advanced cancer. The cause of 
this characteristic clinical sign is oedema of the skin: this is not due to 
direct  infiltration  of  the  skin  by  tumour  but  represents  lymphatic 
obstruction of the breast as a result of axillary metastasis. 
            It is differentiated from inflammatory breast cancer, in which 
cutaneous lymphatics contain tumour emboli.  In  advanced,  untreated 
cases there may be ulceration and fungation.
D, Changes at the nipple                
             Nipple distortion and retraction are common presenting 
features in patients with breast cancer. The discharge associated with 
intraductal cancer is unifocal ,watery or blood-stained. It is multifocal, 
tenacious, and coloured  in  duct ectasia.
            Paget’s disease  is usually a presenting feature of breast 
cancer  in  the  elderly,  although  it  is  occasionally  seen  in  other  age 
groups. It usually represents an underlying intraductal carcinoma 
which may be quite extensive in the breast and which may also exhibit 
an invasive component.  There are  characteristic,  large,  clear  Paget 
cells  origin of which is unknown.
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  LOCALLY ADVANCED BREAST CANCER WITH LIMB 
LYMPHEDEMA
         LOCALLY ADVANCED CA DEVELOPING IN 
                                       GYNAECOMASTIA
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3.6, DIAGNOSIS OF BREAST CANCER
                    There is no indication for a purely clinical diagnosis of 
breast cancer. Confirmatory diagnosis is by pathology and radiology.
3.6.1, PATHOLOGICAL DIAGNOSIS
 A, Fine needle aspiration cytology
                  This method is performed as an outpatient procedure and  
today can also find ER/PR status with immunohistochemistry.
                 The false-negative rate is about 15 per cent and are 
usually due to sampling errors.                  
                 The false positive results occur in about 2 per cent of 
cases  and  could  be  due  to  hyper  cellular  fibroadenoma,  effects  of 
hormone therapy, pregnancy, or lactation on normal breast tissue.
               Aspiration cytology cannot differentiate in-situ or invasive 
cancer but can distinguish ductal from lobular carcinoma  
B, Trucut/Core biopsy
 It is performed under local anaesthesia and gives a histological 
rather than a cytological specimen. It differentiates insitu from invasive 
disease , detects ER/PR status and the grade of the tumour 
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C, Incision / Excision biopsy
It is rarely used only if FNAC or core biopsy fails. It  can confirm 
or  exclude  malignant  disease. Incision  biopsy   only  when  the 
tumour > 3 cm in size. 
3.6.2 RADIOLOGICAL DIAGNOSIS
 A, Mammography
            A high level of sensitivity and specificity is now available using 
modern mammographic techniques. 
The classic features of breast cancer on mammography are:
A. Tissue Asymmetry
B. Mass Effect
C. Microcalcification
D. Skin Thickening
E. Nipple Inversion           
            The  combination  of  mass  effect  with  localized 
microcalcification has the highest predictability for a malignancy. 
It  detects  potential  multicentricity and  acts  as  a  base-line  for 
radiological evaluation of the breast in the years after initial diagnosis.
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                       MAMMOGRAM
   
             PHYLLODES TUMOUR           INFILTRATING DUCTAL CA 
         
              
        
     AXILLARY NODES- MLO VIEW
                      
  
              DCIS- PLEOMORPHIC CALCIFICATIONS
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                                  MRI OF THE BREAST
             
              
LOCALLY ADVANCED BREAST CANCER WITH LIMB 
LYMPHEDEMA
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B, Ultrasound: 
                   Ultrasound remains the primary means of differentiating a 
cystic  or  solid  nature  of  a  lesion.  Sensitivity  of  the  ultrasound today 
helps to pick up a 3 mm lesion.
          Its main uses today are:
A. In a nipple discharge a duct ectasia or ductal papilloma 
can be identified.
B. In finding fluid collections post lumpectomy
C. In diagnosing breast abcesses
D. Breast implant rupture and leak
E. Preferred modality in pregnant women 
F. Combined with mammogram in dense breasts
G. Can guide aspirations or biopsies in small areas
C, Magnetic resonance imaging:
                  Magnetic resonance imaging has an established role in 
breast imaging. It exploits the difference in relaxation times of various 
types of  tissue. The breast fat  appears bright on T1 weighted image 
whereas a fluid filled cyst appears bright on a T2 weighted image.    
Its definite uses are :
A. Clarifies if both  USG and  Mammogram  fail 
B. In isolated axillary metastases with negative breast imaging 
C. Distinguishes scar from recurrence in post mastectomy status
D. Gold standard in post reconstruction follow up
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3.7, STAGING
              The purpose of staging is to aggregate cases having an 
approximately similar prognosis.
            Many staging systems have been proposed. The older systems 
used were The Manchester And Columbia  Systems .Today only the 
TNM system is used.
3.7.3 THE TNM CLASSIFICATION :
              The TNM classification as released in 1954 by the International 
Union against Cancer (Union Internationale Contre Cancere) attempted 
to classify breast cancer on a description based on the primary tumour 
(T),  the regional  lymph nodes  (N),  and distant  metastases (M).  This 
system  is the most popular system used till date. 
 Tumour size(T):
        Tx   : primary tumour cannot be assessed
        T0   : no evidence of primary tumour.
        Tis  : carcinoma in situ (DCIS,LCIS, pagets disease of         
                 nipple with no palpable tumour)
T1   : < 2cm in greatest dimension
        T2   :  2 to 5cm in greatest dimension
        T3   : > 5cm in greatest dimension
        T4   : fixation to chest wall or skin
        T4a :  Extension to chest wall
T4b : Skinedema (including peau d orange), 
           Ulceration  and satellite  nodules
                  T4c :  both
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                  T4d :  inflammatory carcinoma
Nodal stage (N):
                          
Nx: regional lymph nodes cannot be assessed
N0: axillary nodes do not contain tumour
N1: mobile involved axillary nodes
N2: fixed axillary nodes
N3:  a, infraclavicular nodes
        b, internal mammary and axillary
 c, supraclavicular lymph node and/ or arm  swelling.
Metastasis (M):
               
Mx: presence of distant metastases cannot be assessed
M0: no distant metastases.
M1: distant metastases present.
Stage grouping:
STAGE TUMOUR NODE METASTASIS
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage Iia
T0
T1
T2
N1
N1
N0
M0
Stage Iib T2T3
N1
N0 M0
Stage IIIa
T0
T1
T2
T3
N2
N2
N2
N1,N2
M0
Stage IIIb T4 N0,N1,N2 M0
Stage IIIc ANY T N3 M0
Stage IV ANY T ANY N M1
37
3.8 TREATMENT OF CARCINOMA OF THE BREAST
               The treatment of carcinoma breast has changed, more so in 
the past few years.  We have witnessed fundamental  changes in our 
approach, with decreasing reliance on radical surgical excision of the 
primary tumour and associated regional lymph nodes. 
                This is mainly due to a better understanding of  the spread 
of breast cancer, a greater appreciation of the  systemic aspects of 
the disease, and increased realization that variations in local regional 
treatment are unlikely to alter prognosis.
             Hence a multi- modal approach is adopted to obtain the best 
results in terms of patient survival and disease free survival  
            The modalities are surgery, chemotherapy, radiotherapy and 
hormone therapy and immunotherapy  . Surgery is the main modality in 
all stages except when systemic disease is present .
3.8.1 SURGERY :              
              The surgical options  available today are 
                                    A, Breast conservation surgery               
                                    B, modified radical mastectomy (patey’s)
                                    C, palliative simple mastectomy 
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A, Breast conservation surgery :  (BCS)
               Patient choice is one of the important criteria in electing this  
modality . 
I, Indications for breast conservative therapy 
              Tumour characteristics, the position of the cancer in the breast,  
and  the  nature  of  the  breasts  themselves.  Mammography  is   an 
essential  preoperative  investigation  to  determine  the  presence  of 
multicentric tumours.   
1,Tumour size :                  
                         Tumour is less than 4cm in diameter (mastectomy if the 
tumour is more than 3 or 4cm in diameter).
2, Tumour fixity :                               
                          No fixation to the underlying muscle or overlying skin. 
3, Tumour breast ratio :
                          Favourable tumour breast ratio allows breast 
conservation surgery to be an option. 
II, Contraindications  to breast conservation surgery
         1, Absolute :
                           A, Multicentricity. 
                           B, Patients with a second tumour in the breast,  
                           C,  Collagen vascular diseases
                           D, Prior irradiation 
                           E, Pregnancy
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                           F, Positive lumpectomy margins 
         2, Relative :
                            A, Multifocality
                            B, Centrally located tumours 
                            C, Poor tumour differentiation
B, Modified Radical Mastectomy (Patey’s)
            Modified radical mastectomy refers to a procedure combining 
total  mastectomy  with  removal  of  axillary  lymph  nodes  in 
continuity with the mastectomy specimen. It is the most widely used 
procedure  to  treat  operable  breast  cancer  and  is  the  alternative  to 
breast-sparing procedures. 
            The patient is left with intact musculature around the shoulder 
and a situation that is well suited to prosthetic reconstruction. 
The structures removed in a modified radical mastectomy are :
A. The whole breast
B. Skin overlying the tumour with nipple areola complex
C. All of fat, fascia and lymph nodes of the axilla. 
D. The pectoralis minor is either divided or retracted or removed .
E. Axillary  vein,  nerve  to  serratus,  subscapular  neurovascular 
bundle are preserved 
The survival of patients with negative axillary nodes was 82% at 10 
years with a local  recurrence rate of  5%. For patients with  positive 
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nodes,  the  survival  was  48%,  very  similar  to  results  with  radical 
mastectomy. 
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SARCOMA OF THE BREAST
POST MRM FIELD
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            Scanlon modified the Patey procedure by dividing the 
pectoralis  minor muscle,allowing removal  of  apical  (level  III)  nodes 
and preservation of the lateral pectoral nerves to the major muscle.
             Auchincloss differs from the Patey procedure by retracting 
the  pectoralis  minor  muscle.  This  modification  limits  the  complete 
removal  of  high  axillary  nodes  but  is  justified  by  Auchincloss,  who 
calculated that only 2% of patients will potentially benefit by removal of 
the highest level nodes
Management of axillary nodes 
             Axillary dissection acts as a guide to staging and prognosis. 
It dictates the need for adjuvant therapy with chemotherapy, irradiation, 
or hormonal therapy. It provides  good local control of disease in the 
axilla as untreatable axillary metastases can cause much morbidity. 
Axillary nodal clearance 
             Block dissection of axillary nodes accurately stages the axilla, 
both  qualitatively  and  quantitatively,  and  has  the  advantage  that  it 
provides a good mechanism for tumour control. 
            However,  if there is bulk nodal disease with metastases 
greater  than  2cm  in  diameter  full  surgical  axillary  clearance  is 
usually preferred.
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Axillary nodal sampling:
                  If done properly it provides qualitative data as good as those 
obtained from clearance, allows appropriate patients to be treated with 
radiotherapy, and provides a rational basis for systemic treatment.      
Sentinel lymph node biopsy
  The sentinel lymph node is the first node to receive lymphatic 
drainage from the tumour. Blue dye or radio-active colloid is injected 
around the tumour and the first  node to show a blue colour  or  high 
radio-activity is sent for histopathological examination. 
             Positive  a Complete axillary dissection 
   Negative   Further exploration is abandoned and
Complications of limb edema and arm stiffness are avoided
        Absolute  contraindications  are  palpable  axillary  lymph node 
metastases, multi focal breast cancer or prior breast or axillary surgery  
3.8.2 Local recurrence after treatment of breast cancer
                 Locally recurrent disease must be distinguished from regional 
recurrence; the two are often confused. Local recurrence is that seen 
in the breast after conservative therapy or on the chest wall after 
mastectomy; regional recurrence denotes recurrent disease in regional 
lymph nodes.
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      Regional recurrence associated with widespread metastatic 
disease and it is therefore mandatory to identify distant metastases.
                 In general, the more radical the treatment the lower the 
incidence of local recurrence. The lowest local recurrence rate (2 per 
cent  for  stage  I  disease)  has  been  recorded  after  extended  radical 
mastectomy.  The overall incidence of local recurrence after breast 
conservation is about 10 %.
Factors predisposing to local recurrence:
A, Positive axillary nodes :
Recurrence   is  more common in  patients  with  positive  axillary 
nodes.  It  has  therefore  been  suggested  that  as  well  as  giving 
radiotherapy  to  all  patients  after  partial  mastectomy,  the  chest  wall 
should be irradiated after total mastectomy if disease has spread 
to the nodes. 
B, Tumour size:
 Tumour size has been shown to be associated with increased 
incidence of  local  recurrence after  both total  mastectomy and breast 
conservation. Therefore  in T3 and T4 lesions  adjuvant irradiation is 
recommended.
         Again, there is no evidence that this improves survival, although it  
reduces local recurrence.
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C, Positive surgical margins:
                  Positive surgical margins are an important risk factor for  
recurrence.  Reason  being  either  inadequate  surgical  technique  or 
extensive in-situ disease.  Hence multifocality is an important factor 
predisposing to local recurrence.
D. Other factors : 
            High tumour grade, lymphatic or vascular invasion, and 
young age are also associated with recurrent disease.
Rationale of systemic approach :
             Systemic metastatic disease  has a median survival after  
diagnosis of 14 months. The systemic component of breast cancer, as 
described  above,  indicates  that  either  the  patient  is  cured  by  local 
treatment  or  that  death occurs  from metastatic  disease at  about  the 
same time that she would have died without local intervention.
3.8.3 ADJUVANT CHEMOTHERAPY
              A combination of  cyclophosphamide, 5-fluorouracil, and 
methotrexate  has  been  most  widely  used  .  The  initial  study 
evaluating this combination therapy in breast cancer showed a 30 per 
cent reduction in mortality in patients receiving  and the effect was 
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most clearly  apparent  in  premenopausal  women with  1 to 3 positive 
nodes. 
              Adjuvant polychemotherapy is now recommended for all 
node-positive women aged less than 50.  Chemotherapy causes a 
pharmacological castration and ovarian ablation. 
Non-Metastatic Breast Cancer
A, Node-Negative Patients :
• CMF / FAC /AC 
B, Node-Positive Pateints 
• FAC/ CMF / AC
• CEF / EC  where  E = Epirubicin 
• TAC  where T = Docetaxel 
Recurrent or Metastatic Breast Cancer 
• CAF/ CMF/ CEF /AC / EC / AT 
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DRUG ABBREVIATION DOSE
Cyclophosphamide C
500 mg/m2 /IV
100-200 mg/m2 /PO
Adriamycin A 40-50 mg/m2 /IV
5-Flourouracil F 400-500 mg/m2 /IV
Epirubicin E 110-120 mg/m2 /IV 
Docetaxel T 60-100 mg/m2 /IV
• FAC  all on DAY1  repeat every 28 days
• CMF classical   Cyclophosphamide PO 14 days
M & F on DAY 1 and 8 
Repeat every 28 days
• CMF     all on DAY 1  Repeat every 21 days
• AC  A on DAY1, C on DYAS 3-6
Repeat every 21 days
                          
3.8.4 ADJUVANT HORMONAL THERAPY
             Hormone therapy is offered to  all women with hormone 
receptor-positive  invasive  breast  cancer regardless  of  size or  the 
number of lymph nodes involved.
             The effect is greatest in patients age over 50 with positive 
nodes, in whom there is a 20 per cent reduction in annual mortality. 
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This translates to an 8 per cent reduction in 10-year mortality. There 
is a small, yet still significant, effect in node-negative individuals.        
Tamoxifen:
An important effect of adjuvant tamoxifen  is  that it reduces the 
risk  of  contralateral  breast  cancer  by  39  per  cent.   The  role  of 
adjuvant tamoxifen is now well established in women over the age 
of  50.  Newer  generation  drugs  like  raloxifene  and  toremifene  are 
available but tamoxifen is most widely used.
          Tamoxifen at 10 mg bi daily for 5 years is considered standard in 
all  women > 50  yrs  especially  if  node positive.  Aromatase inhibitors 
have an additive effect if used with tamoxifen.
Side effects of tamoxifen include thrombo embolic phenomenon 
, hot flushes , endometrial  cancer and  particularly in premenopausal 
patients  experience  menopausal  symptoms,  nausea,  weight  gain, 
vaginal dryness, or discharge.
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Aromatase inhibhitors:
New study results  now confirm that  aromatase inhibhitors  (Eg. 
Letrozole ) are either better than or equal to tamoxifen in cancer that is 
locally advanced or has spread to other parts of the body. These drugs 
function by preventing estrogen from being produced, but they are only 
effective in women who are past menopause.
Despite these results these drugs are not presently the standard 
in the government setup because of the cost factor and poor follow up 
to draw any conclusions.
LHRH agonists :
Goserelin and leuprolide act  on the pituitary –ovarian axis and 
block estrogen production from the ovaries.
3.8.5 ADJUVANT RADIOTHERAPY:
Radiation is used to destroy cancer cells left behind in the breast, 
chest  wall,  or  lymph  nodes  after  surgery.  Radiation  treatments  are 
usually given at 40 -50 Gray, 5 days a weekin divided doses for 6 to 7 
weeks. 
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Indications :
• All cases of breast conservation therapy. 
• Tumour size  larger than 5 cm in size, 
• Positive margins after mastectomy
• 4 or more positive lymph nodes and / or  extra capsular spread 
• High grade with lymphatic / vascular invasion
Types of therapy : 
A, External beam radiation: Most common method 
B, Internal radiation / brachytherapy/ interstitial radiation.
Field of therapy:
A,Post lumpectomy: The entire breast , infraclavicular/ internal 
mammary nodal areas withextra boost to tumour bed 
B, Post mastectomy : The entire chest wall  + /- axilla 
Side effects:
 Skin changes and lymphedema of the ipsilateral arm 
Partial breast radiation : Radiation over a much shorter period  only to 
the part of the breast with the cancer is still experimental. 
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3.8.6 IMMUNOTHERAPY
Trastuzumab (Herceptin) is a drug that is an antibody directed 
against the HER-2/neu receptor on the surface of the breast cancer 
cells
Indication : 
Metatstatic disease with breast cancer with HER-2/neu receptor 
and nodal positivity.
 It is cardiotoxic as heart muscle cells also have the HER-2/neu 
receptor. It should be used cautiously when combined with other heart-
damaging drugs such as anthracyclines (doxorubicin and epirubicin).
3.9 LOCALLY ADVANCED CANCER (STAGE III)
           Locally advanced tumours are defined as those more than 5cm 
in  diameter  or  those  with  fixed  axillary  nodes  in  which  there  is  no 
evidence of distant metastases. The management of these cancers has 
been somewhat disappointing because of poor local tumour control and 
the high incidence of  subsequent  metastatic  disease,  resulting  in  an 
overall survival rate of 20 per cent or less.
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Role of neoadjuvant therapy :
Preoperative  systemic  chemotherapy  gives  the  best  results. 
Postoperative  chemotherapy  and  radiotherapy  did  not  improve  the 
survival rate as compared to the control group(2). The agents and their 
dosages used are the same as that of adjuvant setting.
Data   from  the  NSABP  B-27  and  GEPAR-duo  trials  strongly 
support  a  combined  anthracycline  /  docetaxel  (AT) regimen in  the 
neo-adjuvant setting with improved overall and disease-free survival(3), 
although  cardiac  toxicity  underlies  the  necessity  to  optimize  the 
schedule of AT combination(4).
 This is particularly the case in  more aggressive tumors or those 
women  with  lymph  node  involved  cancers.  The  length  of  these 
regimens ranges from four months to six months.
Role of Surgery in LABC :
Surgery  following  neo  adjuvant  therapy  is  usually  a  modified 
radical mastectomy although presently the role of breast conservation is 
being  evaluated  in  this  situation.  Other  procedures  are  not 
recommended.
53
3.10 FOLLOW-UP OF WOMEN WITH BREAST CANCER
Physical  evaluation  is  directed  towards  the  detection  of  local 
regional  recurrence as well  as distant  metastases.  The evaluation of 
local regional recurrence should include detection of new primary breast 
cancers. 
Mammography  is  therefore  recommended  every  1  to  2 
years after initial diagnosis.
 Local recurrence in the breast or in regional lymph nodes can 
be  treated  or  at  least  palliated  with  further  surgery,  irradiation,  or 
chemotherapy.   
  
3.11 MALE BREAST CANCER 
               Breast cancer occurring in the mammary gland of males is 
rare and less than 1% of the incidence in women.  The average age at 
diagnosis is 10 years older in men than in women.  Since  breast tissue 
is scant  in men,  breast  tumors in males involve the pectoralis  major 
muscle more commonly.        
            Histologically, tumors of the male breast are most commonly 
infiltrating ductal carcinomas that are similar in appearance to their 
counterparts in females. Lobular carcinoma, is rarely seen in males. 
Interestingly,  male  breast  cancer  very  often  contains  steroid 
hormone receptors. 
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Studies  found that  84% of tumors arising in male mammary 
glands contain estrogen receptor, and support the high incidence of 
receptors and the frequent hormone sensitivity of male breast tumors.
TREATMENT
                The treatment of carcinoma in the male breast depends on 
the  stage and local  extent  of  the tumor.  If  the underlying pectoral 
muscle is involved, radical mastectomy is the procedure of choice. 
                For  smaller  mobile  tumours,  a  modified  radical 
mastectomy appears to be the procedure of choice with  postoperative 
radiation therapy.
              Node-positive disease portended a worse prognosis in men 
than in women. There is little experience with adjuvant chemotherapy or 
hormonal therapy in male breast cancer. 
Because the majority of these tumors are hormone sensitive, 
the  use  of  adjuvant  tamoxifen  for  node  positive  and  high-risk  node-
negative patients seems logical. 
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3.12 THE PROGNOSIS OF BREAST CANCER
               The natural history of breast cancer is uncertain and survival, 
even after the development of metastases, may be prolonged without 
treatment. Recurrence and subsequent death may occur as long as 25 
years after the original diagnosis.   
  Despite these limitations the analysis of 5 year/10 year survival 
demonstrates that                     
STAGE 5 YR SURVIVAL 10 YR SURVIVAL
I 80 % 50 %
II 50 % 35 %
III / IV 30 % < 25 %
Prognostic factors in breast cancer
              They act as a guide to overall prognosis, but they may also 
determine the need for adjuvant treatment. 
                Overall clinical stage is, therefore, only a relatively poor 
prognostic indicator, and is less important than specific pathological 
and certain biochemical parameters. 
                Multivariant analysis of the various clinical and pathological 
features  show  that  axillary  nodal  disease,  tumour  size,  and 
differentiation are the most important  .          
A, Lymph node metastases
           Nearly all studies show that the presence of  axillary lymph 
node  metastases is  the  most  important  prognostic  determinant. 
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Prognosis  is  a  function  of  the  number  of  lymph  node  metastases, 
although other factors such as level of disease, extranodal spread, or 
size of tumour metastases may be of some minor significance. 
Number of involved nodes Relative survival rate at 5 yrs
0 82 %
1-2 60 %
5-6 47 %
11-12 31 %
20 8  %
B, Tumour size
            Tumour  size  is  the  second  most  important  prognostic 
determinant.  Although  tumour  size  and  lymph  node  metastasis  are 
closely  related  they  are  also  independent  of  each  other  in  terms of 
prognosis..
C, Histological grade
             Grade is classified as I, II, or III on the basis of tubule formation, 
nuclear pleomorphism, and mitotic rate. Mitotic rate is the most powerful 
factor.
             
Tumour grade % distribution
Grade I 20 %
Grade II 40%
Grade III 40%
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D, Tumour type
                There is a relationship between tumour type and prognosis. 
Special types of breast cancer such as pure tubular, mucinous, and 
invasive cribriform carcinoma have an excellent prognosis 
            Infiltrating lobular and medullary carcinoma appear to have 
an intermediate prognosis 
           The grading of classic lobular cancer is also difficult because of 
the nature of  the tumour cells and lack of  histological  pattern in this 
particular type of cancer.
E, Hormonal receptor status
           Such  endocrine  sensitive  tumours  can  be  identified  by 
measurement of oestrogen or  progesterone receptors(PR) within the 
cancer itself.
The oestrogen receptor(ER) is a cytosol protein that can be 
identified using a variety of methods. 
           Previously, the most common method of detection involved the 
incubation  of  the  supernatant  fluid  of  a  tissue  homogenate  with 
radiolabelled  oestrogen.  The  unbound  label  is  then  removed  by 
dextran-coated charcoal or sucrose density centrifugation and an 
assay performed. 
          More recent methods use monoclonal antibodies against the 
receptor; such methods require smaller specimens.
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F, The Hormonal Axis 
Estrogen ER Nucleus   Mrna   ER +PR+ Cell  growth 
            The presence of oestrogen or progesterone receptors within the 
cell has been associated with  an improved short-term prognosis  in 
some studies. They are weak indicators of overall prognosis
G, Other  factors
          Other histological features  with doubtful prognostic importance:
1. Vascular or lymphatic invasion in the breast, 
2. Perineural invasion
3. Tumour necrosis 
4. Mucin production.
F, Newer prognostic factors               
(a) Growth factor indicators:
                                         EGFR (growth factor receptor)
                                         ErbB&sub2; oncogene
(b )Factors relating to tumour invasion:
                                         Cathepsin D
                                        Collagenase activity
(c) Factors relating to growth rate:
                                          p53
                                        S-phase fraction
(d) Factors relating to cell adhesion:
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                                         CD44 glycoprotein
3.13, THE MANAGEMENT OF METASTASES
               The management of metastases demands a multimodality 
approach by surgeons, radiotherapists, and medical oncologists. 
A, Assessment of patients with metastatic disease
                     A full series of staging investigations:
                                         A, Chest Radiography, CT Scan 
                                         B, Abdominal Ultrasound/ CT Scan
                                         C, Bone Scintigraphy
                 Brain scanning is not recommended: the likelihood of this 
investigation detecting asymptomatic recurrence is small.   
   Carcino-embryonic antigen  at present does not have any 
significant   role in  assessment  of  metastatic  breast  cancer  or  the 
evaluation of response to treatment.
B, Prognostic indicators in metastatic disease
1,Disease free interval             
                 The most important prognostic indicator in metastatic 
disease.The  median  survival  of  women who  relapse in  a  single  site 
within 1 year of diagnosis is about 11 months; those who experience a 
disease-free interval of more than 5 years have a survival of up to 40 
months.
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2,The site of metastatic disease 
                Prognosis is better in patients with local regional or bony 
metastases than in those with recurrence in the liver or central nervous 
system. The 
3,Number of metastatic sites 
                  The more the number of sites the worser the prognosis.  
Survival of patients with three sites of metastases is only 50 per cent of 
those with one affected site.
C, TREATMENT OF METASTASES
                  The majority of patients with metastases can be regarded as 
suffering  from  widespread  systemic  disease,  the  use  of  systemic 
therapy is nearly always appropriate. Breast cancer is responsive not 
only to radiotherapy and chemotherapy but also to various endocrine 
therapy.
1, Endocrine therapy
        The effect  is  mediated by oestrogen receptors  .The overall 
response to endocrine therapy in breast cancer is about 30 per 
cent.  Ranges from 60 per cent in  ER+Ve and 10 per cent in ER-Ve 
tumours. Response is proportional to level of oestrogen receptors. If the 
level  of  progesterone receptors is also elevated the response rate is 
likely to be increased.     
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Present Recommendations: 
      --  Tamoxifen is the ideal first-line endocrine therapy
      --  Failure to respond is an indication to stop  endocrine therapy. 
      -- Relapse following an initial response is treated with progesterone 
      -- Subsequent treatment failure is  treated by Aminoglutethimide 
      -- Oophorectomy is  a second-line treatment 
 2, Chemotherapy:
          Response and time for it  depend on the site of  metastatic 
disease: better responses are seen in soft tissue and bone than in 
the liver or central nervous system.
          Cutaneous or lymphatic metastases 3 to 6 weeks;
        Bony metastases  4 or 5 months 
          Vincristine  :  Although  no  survival  advantage,it  is  not 
myelosuppressive and hence preferred.
           Mitomycin  C is most commonly used in combination with 
methotrexate and mitozantrone .(MMM) as a second-line treatment. 
           CMF (cyclophosphamide, methotrexate, and 5-fluorouracil ) is 
most commonly used regimen which has an overall response rate of 
up to 60 per cent. 
           CAF  (Adriamycin, cyclophosphamide and 5-fluorouracil)  is a 
second-line  treatment  following  failure  of  initial  chemotherapy, 
especiall in younger patientswith a poor prognosis, such as those with 
liver metastases. Its toxicity precludes its use in older patients.
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3.14, SPECIFIC MANAGEMENT OF METASTATES
A,Local regional recurrence
          Regional recurrence is always of clinical importance and implies 
a worsening of  prognosis.  However,  it  is  particularly  important  if  it 
occurs in a treated rather than an untreated field. 
        The management of regional recurrence depends on the site of 
relapse. 
Internal mammary or supraclavicular areas 
              Radiotherapy with  endocrine/ chemotherapy as appropriate.
Axillary relapse :                   
                No previous surgery  full surgical clearance
                Previous surgery        Radiotherapy / chemotherapy.
Metastases in the gastrointestinal tract
    B, The liver 
                 --Common site of metastatic spread of breast cancer 
-- Surgical resection has no role
                 -- The prognosis of hepatic metastases is poor, 
                 -- Poor response to  hormone therapy. 
                 -- In young patients with good performance status 
combination chemotherapy, including adriamycin 
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     C, Peritoneal metastases 
                 -- Present as acites or intestinal obstruction. 
                 -- Particularly common in patients with lobular 
                     carcinoma. 
                 -- Systemic combination chemotherapy is required 
 --Surgical intervention should be avoided if possible
      D, Respiratory system
                 -- Metastatic lymphangitis can cause distressing        
                    dyspnoea 
                 -- No role for  surgery  or radiotherapy. 
                 -- Systemic combination chemotherapy 
                 -- Endocrine treatment in older poor-performance 
                      patients.
                 -- Steroids for symptomatic relief.
                 -- Pleurodesis is indicated for persistent pleural 
                    effusion
E, Bony metastases
-- Most common form of secondary spread of breast     
   cancer
-- Pain and pathological fracture are the most common 
   -- Radiotherapy for symptomatic relief 
   -- Chemotherapy – as risk of developing  multiple 
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       metastases 
    --Endocrine therapy with tamoxifen is first-line treatment,             
    -- Pathological fractures–surgical fixation 
    -- Hypercalcaemia –Rehydration with forced diuresis with 
        steroids .Resistant cases – mithramycin or 
        diphosphonates                                                                        
F, Central nervous system metastases
          -- Brain, Spinal cord, Meninges, Epidural space causing cord 
compression.  Primary Radiation therapy with Surgery only for 
cord compression
G, Bone marrow metastases 
          --  Often associated with bony deposits 
          --  Potential leucopenia and thrombocytopenia 
          -- Endocrine / chemotherapy based on performance 
             status, age, and ease of  administration.
65
4.MATERIALS AND METHODS
This  study  was  conducted  on  patients  with  locally  advanced 
breast  cancer  who  were  admitted  and  treated  at  both  Government 
Royapettah  Hospital  ,Chennai  –  14, And  Government  Kilpauk 
Medical College and Hospital, Chennai -10.
Pathological diagnosis was by FNAC for all cases, TRUCUT and 
OPEN BIOPSY as appropriate for each case.
CASE SELECTION CRITERIA:
All cases with breast cancer with  T stage of T3 and above and 
/or nodal stage of N2 and above were chosen. 
Metastatic  breast  cancer  was  ruled  out  from  each  system  by 
appropriate investigations such as :
A, Abdomen and Pelvis  : Ultrasound , CT scan for doubtful lesions
B, Respiratory : X ray chest, CT scan for doubtful lesions
C, Skeletal : X ray of part, Bone scan if normal X ray
D, Brain And Spinal Cord : CT/ MRI as per affordability.
No case of Inflammatory breast cancer was encountered  in this 
study.
In cases that had particular symptoms the same investigations as 
those done to rule  out metastases were performed. Cases were 
reviewed monthly for the first year and two monthly for the second year.
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Clinical  examination at  every  visit,  Liver  function tests every  3 
months, and  an ultrasound abdomen every 3 months were routinely 
performed in cases where there were no specific complaints. 
An Echo cardiogram was  done in  patients  to  evaluate  cardiac 
status before and during the course of  chemotherapy with cardiotoxic 
agents such as adriamycin and taxanes.
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5. PROFORMA
NAME                                                            
AGE                                                           DATE OF ADMISSION
SEX                                                             DATE OF SURGERY 
IP NO:                                                         DATE OF DISCHAGE
PRESENTING COMPLAINTS:
                       Lump
                       Nipple Discharge 
                        Pain 
                        Loss Of Weight /Appetite
      H/O Previous Breast Disease
      H/O Previous Procedures
      MENSTRUAL H/O : 
                              Pre/Post Menopausal
                              Age At Menarche /Menopause
                              Age At First Child Birth /Breast Feeding
      FAMILY H/O : Breast / Ovarian / Colonic Cancer 
      H/O Oral Contraceptive Intake 
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EXAMINATION:
       GENERAL EXAMINATION:         
                          Build And Nutrition
                          Jaundice 
                          Pallor
                          Vital Signs
       SYSTEMIC EXAMINATION:
                          Cardiovascular System
                          Respiratory System
                          Central Nervous System   
                          Abdomen        
        LOCAL EXAMINATION:
LUMP: Site , Size , Shape , Skin Over The Lump 
Warmth, Tenderness, Consistency , Borders
                          Chest Wall Fixity 
NIPPLE: Ulceration , Discharge, Retraction
NODES: Axilla , Supraclavicular of both sides 
     OTHER BREAST 
CLINICAL STAGE:  T__ N__ M__
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INVESTIGATIONS:
                          Hemogram
                          Renal Parameters,Blood Sugar
                          Mammogram , Ultrasound Of Breast
                          Biopsy- Fnac, Trucut, Incision Biopsy 
                          Er/Pr Status
                          X Ray Chest,Ultrasound Abdomen And Pelvis
                          Liver Function Test                                    
PRIMARY TREATMENT MODALITY
CHEMOTHERAPY :Drugs Used, No Of Cycles , Duration
RADIOTHERAPY : Total Dose, Fractions/ No Of Sittings
HORMONE THERAPY:
OTHER: Surgery
RESPONSE TO PRIMARY TREATMENT
                        Partial/ Complete / No Response
                        Nature Of Response : Size , Edema , Nodes
SECONDARY TREATMENT MODALITY
SURGERY : MRM
CHEMOTHERAPY :Drugs Used, No Of Cycles ,Duration
RADIOTHERAPY : Total Dose, Fractions/ No Of Sittings
HORMONE THERAPY
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RESPONSE TO SECONDARY TREATMENT
                        Response / Failure
RELAPSE :                       
                        Nature, 
                        Time Interval Since Treatment
                        Asymptomatic Interval
                        Disease Free Interval 
PERIOD OF FOLLOW UP:   _____  months 
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6. OBSERVATIONS AND DISCUSSION
In this study 50 patients were diagnosed to have locally advanced 
breast cancer and followed during the period 2004 – 2006.
Age:
The youngest patient in this study was 26 yrs old and the oldest 
patient  82  years  of  age  with  the  maximum number  of  cases(  58%) 
occurring in 40- 60 years interval.
Sex:
There was 1 male in this study for whom a radical mastectomy 
was the surgical treatment given.
Menopausal status:
Majority   of  cases(55  %)  were  post  menopausal  .  Peri- 
menopausal  (two)  patients  were  considered  as pre  menopausal  and 
treated similarly .
Mode of presentation:
Post mastectomy status was the most common presentation to 
our  hospital  with  a  painless  lump  being  the  next  most  common 
presentation. 
Stage of presentation:
Majority of the cases belonged to the  TNM stage IIIA (38%) . The 
remainder presented as stage IIB (24%) and IIIB (28%). Very few cases 
presented as stage III C (10%).
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ER/PR status:
Estrogen  /  progesterone  receptor  status  was  done  only  for  7 
cases and hence no particular inference could be obtained from it in this 
study.
Treatment modalities:
I,  Surgery followed by adjuvant chemotherapy : 33/ 50 (66%)
A, Surgery: Modified radical mastectomy/ simple mastectomy/
  lumpectomy 
B, Adjuvant therapy:
Chemotherapy – FAC/ CMF 
Radiotherapy – 45Gy/ 50 Gy
Hormone therapy – Tamoxifen  
II, Neo adjuvant therapy followed by surgery:13/ 50 (26%)
Chemotherapy – CMF / FAC
Radiotherapy – 70 Gy ( 1 case) 
Surgery – modified radical and radical mastectomy
III, Chemo-endocrine manipulation only : 4 out of which 3 cases  
      showed poor response and one patient was not fit for surgery 
Margins:
Surgical  margins were  positive in 7 cases and out  of  which 4 
cases had a loco-regional recurrence and a recurrence rate of 57 %. 
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Pathology:
Infiltrating  ductal  carcinoma   (  NOS  )  was  the  most  common 
pathological diagnosis with one case being a medullary carcinoma .
Recurrence:
A total of 17 patients had recurrences in which  12 cases (70%) 
had loco- regional recurrences and 4 patients(23%) had pure systemic 
(distant)  recurrences.  One  patient  (7%)  had  both  loco-regional  and 
systemic recurrence occurring at the same time.
Of the  12 loco- regional recurrences 7 cases (58%) occurred in 
the chest wall, 1 case (8%)  had pure axillary recurrence, 2 cases (16%) 
had both. 2 cases(16%) had supraclavicular nodal recurrence .
Systemic recurrence were 5 of the total 17 cases , 2 occurred in 
the liver( 40%) and 3 cases had bone secondaries ( 60%).
Of the 17 recurrences , 15 cases belonged to the arm which had 
surgery with adjuvant therapy as the treatment modality whereas only 2 
cases belonged to the neo-adjuvant therapy followed by  surgery arm.
10 out  of  those  15  cases  (66%)  had  recurrence  in  the  first  6 
months following initiation of adjuvant treatment. The remaining 5 cases 
( 34%) relapsed within the subsequent 6 months .
The arm which had only chemo-endocrine manipulation did not 
have an attempt to cure although one case had a distant metastasis 
identified during follow up and considered as a recurrence.
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Recurrence interval :
The shortest recurrence interval  was 3 months and the longest 
was 10 months leading to a Mean Recurrence interval of 6.05 months. 
The  mean  recurrence  interval  in  the  arm  with  surgery  followed  by 
adjuvant  therapy was  5.5  months  and in  the  arm with  neo-adjuvant 
therapy as the initial treatment was 7 months.
Treatment of recurrences:
Chest wall and or axillary disease was treated with radiotherapy 
+/- chemotherapy . Revision surgery was done in case of  pure axillary 
relapse with chemotherapy . 
Supraclavicular recurrences with radiotherapy +/- chemotherapy.
Bone secondaries were treated with radiotherapy .
          Liver secondaries with chemotherapy ( CEF/CMF ).
Follow up:
The period of follow up ranged from a minimum of 3 months to a 
maximum of 20 months with a mean follow up period  of 8.3 months. The 
mean period of follow up  in patients without recurrences:
A, Surgery followed by adjuvant chemotherapy : 7 months
          B, Neo-adjuvant therapy followed by surgery : 11 months.
Disease free survival:
The  number  of  months  between the  discharge from secondary 
treatment to that of occurrence of symptoms was taken as disease free 
interval.  The  average  disease  free  survival  was  7.2  months  with  a 
minimum period of 3 months and a maximum of 20 months. 
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7.CONCLUSIONS
Age:
The most common age for presentation of LABC was from 40 to 
60 years of age.
Sex:
It  is  most  common  in  female  sex.  Male  breast  cancer  most 
commonly presents as LABC.
Menopausal status:
Post menopausal cases comprised the largest group of patients 
presenting with LABC.
Mode of presentation:
Post mastectomy status was the most common presentation with 
a painless lump being the next most common presentation. 
Stage of presentation:
Majority of the LABC cases belonged to the  TNM stage IIIA .
Treatment modalities:
 Surgery with or without adjuvant chemotherapy  was the most 
common treatment( 66 %) given to patients outside our hospital as per 
this study 
Neo  adjuvant  therapy  (26  %)  followed  by  surgery  was  the 
treatment offered to patients treated primarily in this institute.
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Margins:
 Positive  Surgical  margins   led  to  high  rate  of  loco-regional 
recurrences .
Pathology:
Almost all cases were Infiltrating ductal carcinoma  ( NOS ) type
Recurrence:
Recurrence rate was found to be 88% in the arm with surgery 
with  adjuvant  therapy of  which 66% (10/  15) recurred in the first  six 
months and remaining 34% in the subsequent 6 months.
A recurrence rate of 12 % (2/17) in the arm with  neo-adjuvant 
therapy followed by  surgery of which 50% recurred in first six months 
and 50% in next six months.
Recurrence interval :
The time interval for recurrence to occur was on an average 6 
months.
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8.SUMMARY
Locally advanced breast cancer commonly:
 Presents in the fifth to sixth decade of life.
 Presents as a painless lump in un-intervened cases.
 Presents in the post menopausal  group and  with a 
higher stage.
 Has a good disease control  if  treated first  by  neo-
adjuvant therapy followed by surgery.
 Has  early  loco-regional  and  distant  recurrences  if 
managed by non standard protocols.
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ABBREVIATIONS USED IN THE MASTER CHART
R -- Right 
L -- Left
C/F -- Clinical features
Rec. int -- Recurrence interval
Dis free -- Disease free interval
Post mastec -- Post mastectomy status
Rec lump -- Recurrent lump
Simple mast. -- Simple mastectomy
Axi. Dis -- Axillary dissection
SCLN -- Supraclavicular nodes
Multi bone mets -- Multiple bone metastases
ND -- Not done
NA -- Not applicable
Neg -- Negative
Posi -- Positive
Re MRM -- Revision modified radical mastectomy
Spinal -- Spinal metastases
Pelvic -- Pelvic metastases
Gy -- Gray
Cy -- Cycles
